
Hasten Biopharmaceuticals is a biopharmaceutical company spanning R&D, production and commercialization, addressing chronic diseases and critical care patients.
hastenpharma.comCrawled Nov 21, 2026
Haisen Biopharma, a biopharmaceutical company covering research, development, production, and commercialization across the entire industry chain, was founded in 2020 by Kangqiao Capital, Hefei Investment Group, and Feidong County of Hefei. In 2023, it secured new funding from investors including Kangqiao Capital and Mubadala Investment Company for acquisitions and innovation pipeline development.
Everest Medicines conditionally acquires the full equity stake in Hasten Biopharmaceuticals (Asia) Limited through its subsidiary, EverSea Medicines (Singapore) Pte. Ltd. The deal expands Everest’s regional footprint in Asia, combining Hasten’s biopharmaceutical assets with Everest’s discovery and commercialization capabilities. Both companies operate in the development of innovative therapeutics, targeting growth in the Asia-Pacific market.
Everest Medicines partners with Hasten to commercialize six mature drug assets targeting critical care, cardiovascular, and metabolic diseases. The agreement leverages Everest’s established services to support Hasten’s portfolio expansion. Both companies collaborate under a license agreement to accelerate market access for these therapies.
Hasten Biopharmaceutical acquires 14 legacy products from Celltrion, expanding its biopharmaceutical portfolio. The deal aligns with CBC’s investor-operator model, which aims to accelerate asset acquisition and global growth for its portfolio companies. The transaction leverages CBC’s operational expertise to drive strategic expansion for Hasten.
Hasten Biopharmaceutical acquires 14 branded biopharmaceutical products from Celltrion, expanding its market presence across Pan-Asia. The deal also grants Hasten Marketing Authorization Holder (MAH) rights for these products in eight countries, including South Korea, Singapore, Thailand, and Australia. This move strengthens Hasten’s regional distribution and regulatory control in key markets.
Hasten Biopharma secures commercial rights for Roche’s antibiotic **Rocephin®** in China. The deal aligns with the company’s existing **critical care portfolio**, expanding its market presence in the region.
Hasten Biopharma completes the acquisition of five Takeda-developed cardiovascular and metabolism prescription drugs for the Chinese market. The portfolio expands Hasten’s product lineup in China, where the drugs are already sold. CBC Group, Asia’s largest healthcare-focused investment firm, backs Hasten alongside Hefei Industry Investment Group and Feidong County’s local government.